Nektar Therapeutics

Update in progress

NKTR (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Nektar Therapeutics is a biopharmaceutical company focused on immunotherapy research and development. Its pipeline includes rezpegaldesleukin (Phase 2b) for autoimmune and inflammatory disorders; NKTR-0165 for ulcerative colitis, vitiligo and multiple sclerosis; NKTR-0166 for autoimmune disease; NKTR-422 for fibrotic diseases; and NKTR-255 for solid tumors and diffuse large B-cell lymphoma. It collaborates with Takeda, AstraZeneca, UCB, Roche, Bausch Health, Pfizer, Bristol-Myers Squibb and Merck KGaA. Founded 1990, based in San Francisco.

Company score

Sentiment: 0.34; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.22; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.03; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.07; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.21; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive